2,4-dichloro-benzoic acid, p-tolyl ester | 92153-11-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: 2,4-dichloro-benzoic acid, p-tolyl ester
• 英文别名: 2,4-Dichlorobenzoic acid, 4-tolyl ester；(4-methylphenyl) 2,4-dichlorobenzoate
• CAS: 92153-11-2
• 化学式: C₁₄H₁₀Cl₂O₂
• 分子量: 281.138
• InChiKey: FZQYSSYQXKFNJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
  申请人：——

  公开号：US20040198727A1

  公开（公告）日：2004-10-07

  The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

  本发明提供了一种抑制哺乳动物细胞，包括人类细胞，特别是DNA损伤诱导的G2检查点的细胞周期G2检查点的组成物和方法。具体而言，本发明提供了一种通过废除细胞周期G2检查点来使细胞对DNA损伤剂敏感的组成物和方法。本发明的化合物用于治疗增生性疾病，如癌症。本发明提供了一种选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗敏感的组成物和方法。
• Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments
  申请人：Kawabe Takumi

  公开号：US20060122269A1

  公开（公告）日：2006-06-08

  The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

  该发明提供了一种抑制哺乳动物细胞，包括人类细胞中的细胞周期G2检查点，特别是DNA损伤诱导的G2检查点的组合物和方法。具体而言，该发明提供了通过废除细胞周期G2检查点来使细胞对DNA损伤剂敏感的组合物和方法。该发明的化合物可用于治疗增殖性疾病，如癌症。该发明提供的组合物和方法可选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗方法敏感。
• COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS
  申请人：KAWABE Takumi

  公开号：US20080227827A1

  公开（公告）日：2008-09-18

  The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

  本发明提供了一种抑制细胞周期G2检查点，特别是DNA损伤诱导的G2检查点，在哺乳动物细胞，包括人类细胞中的组合物和方法。具体而言，本发明提供了一种通过废除细胞周期G2检查点使细胞对DNA损伤剂敏感的组合物和方法。本发明的化合物用于治疗增殖性疾病，如癌症。本发明提供了一种选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗方法敏感的组合物和方法。
• 抗癌治療の効力を推定するための感受性試験
  申请人：株式会社 キャンバス

  公开号：JP2007501608A

  公开（公告）日：2007-02-01

  本開示は、種々の抗癌治療に対する癌細胞の感受性を決定するための方法、およびこれらの治療の効力を推定するための方法を提供する。具体的には、本開示は、インビトロで患者の癌細胞を候補抗癌治療に曝した後に、患者の癌細胞の感受性を決定することに基づいて、患者における１種以上の候補抗癌治療の効力を推定するための方法を提供する。本開示は、患者の癌細胞のインビトロでの感受性試験および代理宿主に移植したこの患者の癌細胞の代理インビボ効力試験を使用することによって、候補抗癌治療の効力を推定する方法をさらに提供する。本開示は、患者にとって最も有効な抗癌治療を選択し、それによって、効果のないまたは不要な処置を避けるための方法をさらに提供する。

  本公开提供了确定癌细胞对各种抗癌疗法的敏感性以及估计这些疗法疗效的方法。具体来说，本公开内容提供了基于在体外将患者的癌细胞暴露于候选抗癌疗法后确定患者癌细胞的敏感性来估计一种或多种候选抗癌疗法对患者的疗效的方法。本公开进一步提供了一种方法，通过对患者的癌细胞进行体外敏感性测试，以及对植入代宿主体内的患者癌细胞进行代理体内疗效测试，来估计候选抗癌疗法的疗效。本公开进一步提供了为患者选择最有效的抗癌疗法的方法，从而避免无效或不必要的治疗。
• Sensitivity test to predict efficacy of anti-cancer therapies
  申请人：Kawabe Takumi

  公开号：US20060014157A1

  公开（公告）日：2006-01-19

  The present disclosure provides methods for determining the sensitivity of cancerous cells to various anti-cancer therapies and predicting the efficacy of these therapies. Specifically, the present disclosure provides methods for predicting the efficacy of one or more candidate anti-cancer therapies in a patient, based on determining the sensitivity of the patient's cancerous cells after exposure to candidate anti-cancer therapies in vitro. The disclosure further provides methods for predicting the efficacy of candidate anti-cancer therapies by using an in vitro sensitivity test of the patient's cancerous cells and a surrogate in vivo efficacy test of the patient's cancerous cells grafted into a surrogate host. The disclosure further provides methods for selecting the most efficacious anti-cancer therapy(s) for a patient, thereby avoiding ineffective or unnecessary treatments.

  本公开提供了确定癌细胞对各种抗癌疗法的敏感性并预测这些疗法疗效的方法。具体地说，本公开提供了基于确定患者癌细胞在体外暴露于候选抗癌疗法后的敏感性来预测患者体内一种或多种候选抗癌疗法疗效的方法。本公开进一步提供了通过使用患者癌细胞的体外敏感性测试和患者癌细胞移植到代宿主体内的代体内疗效测试来预测候选抗癌疗法疗效的方法。本公开进一步提供了为患者选择最有效的抗癌疗法的方法，从而避免了无效或不必要的治疗。

表征谱图